US 11,883,422 B2
Glycan therapeutic compositions and related methods thereof
Geoffrey A. von Maltzahn, Boston, MA (US); Yvonne J. Yamanaka, Cambridge, MA (US); Jared Silverman, Brookline, MA (US); John Miles Milwid, Cambridge, MA (US); Jacob Rosenblum Rubens, Cambridge, MA (US); and John M. Geremia, Watertown, MA (US)
Assigned to DSM Nutritional Products, LLC, Parsippany, NJ (US)
Filed by DSM Nutritional Products, LLC, Parsippany, NJ (US)
Filed on Jun. 30, 2021, as Appl. No. 17/363,597.
Application 17/363,597 is a continuation of application No. 17/099,412, filed on Nov. 16, 2020, abandoned.
Application 17/099,412 is a continuation of application No. 16/140,091, filed on Sep. 24, 2018, granted, now 10,894,057.
Application 16/140,091 is a continuation of application No. 15/568,243, abandoned, previously published as PCT/US2016/029082, filed on Apr. 23, 2016.
Claims priority of provisional application 62/278,333, filed on Jan. 13, 2016.
Claims priority of provisional application 62/238,112, filed on Oct. 6, 2015.
Claims priority of provisional application 62/238,110, filed on Oct. 6, 2015.
Claims priority of provisional application 62/216,997, filed on Sep. 10, 2015.
Claims priority of provisional application 62/216,995, filed on Sep. 10, 2015.
Claims priority of provisional application 62/152,017, filed on Apr. 23, 2015.
Claims priority of provisional application 62/152,011, filed on Apr. 23, 2015.
Claims priority of provisional application 62/152,007, filed on Apr. 23, 2015.
Prior Publication US 2021/0401861 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/702 (2006.01); A61K 45/06 (2006.01); A61K 31/716 (2006.01); A61K 31/733 (2006.01); A23L 33/125 (2016.01); A23L 33/135 (2016.01); A61P 3/02 (2006.01); A61P 43/00 (2006.01); A61P 1/00 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 35/741 (2015.01)
CPC A61K 31/702 (2013.01) [A23L 33/125 (2016.08); A23L 33/135 (2016.08); A61K 31/716 (2013.01); A61K 31/733 (2013.01); A61K 35/741 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 3/02 (2018.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61P 43/00 (2018.01); A23V 2002/00 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method for reducing inflammation of a gastrointestinal inflammatory disease in a subject having an immune imbalance, comprising administering to the subject an effective amount of a composition comprising a glycan therapeutic preparation, wherein:
i) the glycan therapeutic preparation comprises branched glycans comprising glucose, galactose, arabinose, mannose, fructose, xylose, fucose, or rhamnose glycan units;
ii) the glycan therapeutic preparation comprises an average degree of branching (DB) of at least 0.01;
iii) at least 50% of the glycans in the glycan therapeutic preparation have a degree of polymerization (DP) of at least 3 and less than 30 glycan units; and
iv) the ratio of alpha- to beta-glycosidic bonds present in the glycans of the glycan therapeutic preparation is between about 1:1 to about 5:1; thereby reducing inflammation of the gastrointestinal inflammatory disease in the subject having the immune imbalance.